CNS Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of CNS Pharmaceuticals generated cash of -$14,140,031, which is less than the previous year. Cash used in financing activities reached the amount of $4,637,246 last year. Net change in cash is therefore -$9,506,686.
Cash Flow
| 2017 | -112.19K | 0 | 222.74K |
|---|---|---|---|
| 2018 | -716.38K | 0 | 1.16M |
| 2019 | -3.55M | -20.12K | 10.25M |
| 2020 | -7.31M | -17.94K | 14.13M |
| 2021 | -13.53M | -5.74K | 4.50M |
| 2022 | -10.55M | -4.42K | 15.61M |
| 2023 | -14.14M | -3.90K | 4.63M |
CNSP Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 10.05M | 5.00M | 14.03M | 7.24M | 555.13K | 110.54K | 0 |
Operating activities | |||||||
Net income | -18.85M | -15.27M | -14.03M | -9.45M | -3.87M | -7.39M | -219.36K |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 4.13K | 11.75K | 13.07K | 11.09K | 1.95K | 0 | 0 |
Stock-based compensation expense | 1.00M | 1.20M | 1.72M | 1.29M | 477.09K | 0 | 119.85K |
| Deferred income tax benefit | 1.00M | 1.20M | 1.72M | 1.29M | 477.09K | 0 | 119.85K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 1.32M | 1.70M | 576.49K | 656.83K | 153.60K | 71.36K | 57.49K |
Cash generated by operating activities | -14.14M | -10.55M | -13.53M | -7.31M | -3.55M | -716.38K | -112.19K |
Investing activities | |||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -3.90K | -4.42K | -5.74K | -17.94K | -20.12K | 0 | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -3.90K | -4.42K | -5.74K | -17.94K | -20.12K | 0 | 0 |
Financing activities | |||||||
Common Stock Issued | 2.31M | 16.03M | 4.65M | 14.22M | 10.29M | 390.5K | 100.91K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | -477.49K | -43.08K | -35K | 0 | 0 |
Cash used in financing activities | 4.63M | 15.61M | 4.50M | 14.13M | 10.25M | 1.16M | 222.74K |
Net Change In Cash | -9.50M | 5.05M | -9.03M | 6.79M | 6.68M | 444.59K | 110.54K |
Cash at end of period | 548.72K | 10.05M | 5.00M | 14.03M | 7.24M | 555.13K | 110.54K |
| Data source | Data source | Data source | Data source | Data source |